Supplementary Figure S1 from Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Pharmacodynamic effects of alisertib and TAK-228 in patient tissue samples
Authors: S. Lindsey Davis, Anastasia A. Ionkina, Stacey M. Bagby, James D. Orth, Brian Gittleman, Joshua M. Marcus, Elaine T. Lam, Bradley R. Corr, Cindy L. O'Bryant, Ashley E. Glode, Aik-Choon Tan, Jihye Kim, John J. Tentler, Anna Capasso, Kyrie L. Lopez, Daniel L. Gustafson, Wells A. Messersmith, Stephen Leong, S. Gail Eckhardt, Todd M. Pitts, Jennifer R. Diamond
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362419223
